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1INTRODUCTION
Erythroderma (also known as "Exfoliative dermatitis," "Dermatitis
exfoliativa") is a generalized inflammatory disorder of the skin
manifesting with erythema and scaling affecting more than 90% of the
skin surface.(1) Primary erythroderma arises on normal looking skin due
to an underlying systemic disorder or because of a drug reaction, while
secondary erythroderma arises from a pre existing dermatoses.
Erythroderma is a morphological reaction pattern of skin having
innumerable underlying causes which include preexisting skin conditions
like psoriasis, atopic dermatitis, contact dermatitis, systemic skin
conditions including malignancy and drug reaction. Even a thorough
clinical examination and investigations may not detect the underlying
causes many a times.(2)
Erythroderma was described by Hebra in 1868.(3) The disease is
usually associated with underlying cuteneous or systemic disorder or drug
intake and rarely it may be idiopathic. Erythroderma affects the skin as
well as other systems of the body giving rise to haemodynamic
disturbances, biochemical derangement, fever, tachycardia,
hypoalbuminemia and pedal edema, in addition to various cutaneous
changes.
2 Treatment addresses the underlying etiology, symptomatic relief
and potential systemic complications.(4) Although its a rare disease, the
mortality rates are low and morbidity related to it is considerably high as
it is often a chronic disease with debilitating signs and symptoms such as
intense pruritis and scaling. Thus it is importance to find the etiology with
the special emphasis on histopathology allowing early and appropriate
intervention for each case.(2)
The present study of 65 cases of erythroderma, carried out in the
Department of Dermatology, Rajiv Gandhi Government General
Hospital, is aimed at studying the etiopathology, clinical features, its
course, evolution and associated systemic derangement.
3REVIEW OF LITERATURE
ERYTHRODERMA
DEFINITION
Erythroderma is a reaction pattern characterised by generalised and
confluent erythema and desquamation affecting more than 90% of the
body surface area and is usually accompanied by lymphadenopathy and
fever.(5,6)
Exfoliative dermatitis, also referred to as erythroderma, is an
inflammatory disorder in which erythema and scaling occur in more or
less genaralized distribution. (4)
 Various synonyms for exfoliative dermatitis or erythroderma have
appeared in the literature(2,7) They are;
1. Dermatitis exfoliativa
2. Pityriasis rubra (Hebra)
3. Erythroderma of Wilson Brock type
4. Erythroderma-red skin (Homme d Rouge)
5. Erythema scarlatiniform
6. Epidemic form of exfoliative dermatitis
7. Generalised exfoliative dermatitis
8. Red man syndrome
4HISTORICAL ASPECTS
In 1868 Von Hebra described this progressive skin disorder as
Pityriasis Rubra of Hebra and Wilson described it as Wilson Brock
disease. Later Wilson suggested the name Dermatitis Exfoliativa in 1870.
Erythema Scarlatiniform is the name suggested by Ferol in1876. In 1891
Savil described it as an epidemic form of Exfoliative dermatitis and a self
limiting disorder associated with infectious agent or drug.(2) The term
erythroderma was introduced by Von Hebra to describe an exfoliative
dermatitis involving more than 90% of the skin surface. Based upon the
clinical course, erythroderma was classified into chronically relapsing
(Wilson–Brocq), chronically persisting (Hebra), and self-limiting
epidemic (Savill) variants. Although of historic interest, these
subdivisions are no longer employed.(8)
ETIOLOGY
Erythroderma is more common in elderly males and precipitating
factors vary according to age. Males are affected between two to three
times more frequently than females.(9) Erythroderma can be caused by a
wide range of cutaneous and systemic diseases. As knowledge and
diagnostic methods improve, the number of cases of erythroderma with
an unidentifiable cause should decrease.(10)
5The disease process reported to be associated with erythroderma
can be classified under the following headings. (6,10-23)
1. Dermatosis
2. Systemic causes
3. Malignancy
4. Infections
5. Drugs
1. DERMATOSIS
? PAPULOSQUAMOUS DISORDERS
Psoriasis Lichen planus
Pityriasis rubra pilaris  Impetigo herpitiformis
? SPONGIOTIC DERMATITIS
Atopic dermatitis Contact dermatitis
Seborrhic dermatitis  Stasis dermatitis
? BULLOUS DERMATOSIS
Pemphigus foliaceus Bullous pemphigoid
Paraneoplastic pemphigus Hailey-Hailey disease
? PHOTOSENSITIVE DERMOTOSIS
Chronic actinic dermatosis
Actinic reticuloid
6? MISCELLANEOUS
Radiation recall dermatitis
Ichthyosis
Erythema gyratum repens
Perforating folliculitis
Pseudolymphoma
Histiocytosis
Mastocytosis
Rosai-Dorfman disease
2.  SYSTEMIC CAUSES
? COLLAGEN VASCULAR DISORDERS
Subacute cutaneous lupus erythematosis
Lupus erythematosis
Dermatomyositis
Reiter’s syndrome
? ENDOCRINE DISORDERS
Thyrotoxicosis
Hypercalcitonemia
? OTHERS
Acute graft vs host disease
          Sarcoidosis
7Postoperative transfusion induced
Idiopathic hypereosinophilic syndrome
3.  MALIGNANCY
? LYMPHOPROLIFERATIVE
Cuteneous T cell lymphoma
Sezary syndrome
B cell lymphoma
Angioimmunoblastic T cell lymphoma
Papuloerythroderma of Ofuji
Hodgkin’s lymphoma
Castleman disease
Cutaneous anaplastic large cell lymphoma
Adult T cell leukemia
Acute myeloid leukemia
Myelodysplastic syndrome
Acute myelomonocytic leukemia
Multiple myeloma
Angioimmunoblastic lymphadenopathy
Reticulum cell sarcoma
Chronic eosinophilic leukemia
Cuteneous lymphoid hyperplasia
8? SOLID TUMORS
Lung
Liver
Thyroid
Esophagus
Prostate
Gall bladder
Stomach
Rectum
Cervix
Ovary
Breast
Fallopian tube
Melanoma
Buschke- Loewenstein tumor
4.  INFECTIONS
? FUNGAL
Dermatophyte
Congenital cutaneous candidiasis
Histoplasmosis
9? BACTERIAL
Tuberculosis
Congenital syphilis
? PARASITE
Norwegian scabies
Leishmaniasis
Toxoplasmosis
? VIRAL
Hepatitis C
HIV
Human herpes virus
? TOXIN MEDIATED INFECTIONS
Staphylococcal scalded skin syndrome
Toxic shock syndrome
5. DRUG REACTION
? ANTIBIOTIC
Doxycycline          Gentamicin
Sulfonamides Rifampin
Penicillins Minocycline
Cephalosporins Neomycin
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Tetracyclines Quinidine
Streptomycin sulfate Vancomycin
Isoniazid Sulfasalazine
Quinine & Chloroquin  Teicoplanin
Aztreonam Ribostamycin
? ANTIVIRAL
Indinavir
Zidovudine
Dideoxyinosine
Interferon alfa
? ANTILEPROMATOUS
Dapsone
Clofazimine
? ANTIFUNGAL
Terbinafine
? ANTICONVULSANTS
Barbiturates Carbamazepine
Phenytoin sodium Phenobarbital
Lamotrigine
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? CARDIAC DRUGS
Quinidine Diltiazem
Practolol Isosorbide dinitrate
Amiodarone Nifedipine
Captopril Thiazide
Mexiletine
? HEAVY METALS
Arsenic Gold
Mercury agents Bismuth
? ANALGESICS
Aspirin Piroxicam
Fenoprofen Flurbiprofen
Diclofenac Celecoxib
? DIABETICS
Sulfonylureas Chlorpropamide
? CHEMOTHERAPHY
5-Fluorouracil           Imatinib
Vinca alkaloids Cisplatin
Doxorubicin Carboplatin
Mitomycin C Pentostatin
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? ANTIPSYCHIATRIC
Barbiturates Chlorpromazine
Phenothiazines Bupropion
Lithium
? MISCELLANEOUS
Antimalarials Cimetidine
Iodides Codeine
Epoprostenol Ephedrine
Allopurinol Erythropoietin
Potassium thiocyanate Interleukin - 2
Diethyl stilbestrol Omeprazole
Vitamin A Ranitidine
Leflunomide Retinoids
Chlorpromazine Thalidomide
Tumor necrosis factor- Alpha Tramadol
In T Hasan, CT Jansen studied 50 cases of erythroderma of which
21 had pre existing dermatoses as a causative factor, 6 had topical
sensitization to drugs, 5 had reactions to internal drugs, 2 had mycosis
fungoidosis and 16 had idiopathic erythroderma. (24)
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Yuan XY et al studied 82 patients of erythroderma from Jan 2003
to Dec 2008, in China. According to this study the most common
causative factors were pre existing dermatoses (72%) followed by drug
reactions (17%), idiopathic (6.1%) and malignancies (4.9%). Among the
pre existing dermatoses, psoriasis is the most common cause (30.5%).(25)
Akhyani had studied 97 cases, of which the most common
causative factors were pre existing dermatoses (59.7%) followed by drug
reactions (21.6%), malignancies (11.3%) and idiopathic (7.2%).
Carbamazepine was the most common drug (57.1%). (26)
Pal  S,  Haroon  TS,  et  al  had  studied  90  cases,  of  which  the  most
common causative factors were pre existing dermatoses (74.4%) followed
by idiopathic (14.6%),drug reactions and malignancies each accounting
for 5.5% . (3)
PR Bharatiya et al had studied 46 cases, of which the most
common causative factors were pre existing dermatoses (67.4%) followed
by drug reactions (21.74%), idiopathic (6.5%) and malignancies
(4.35%).(27)
In various other studies done previously have also showed pre
existing dermatoses as the most common underlying cause.(3,7,28-34)
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Identifying the etiology in every case of exfoliative dermatitis is
not always possible. The correlation between the clinical presentation and
the etiology in exfoliative dermatitis is poor, due to the fact that changes
specific to dermatitis or drug reactions are frequently masked by
nonspecific changes induced by exfoliative dermatitis. A conclusive
clinical-histological correlation thus may demand several biopsies. In
different international studies, the rates of final etiological diagnosis
based on histopathology varied from 15% to 43% of cases submitted for
biopsy.(2,11)
Even after exhaustive investigations, there were cases in which the
etiology of the erythroderma remained uncertain. In cases with
undetermined cause, strict clinical and histological follow up are
mandatory, due to the possibility of omission of drug intake or slow
progression of cutaneous lymphoma. (11)
EPIDEMIOLOGY
In general, the studies have shown a male predominance, with male
to  female  ratio  approximately  1.85:1  to  4:1.  The  average  age  of  disease
onset among the patients varies from 41 to 61 years.(3,9,10,11,15,35-38)
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Hansen and Jansen reported a incidence of 1 to 2 / 100,000.(24)
Mean duration of the illness was 1.44 years in a study(39) and in a another
study it was 11.81 years.(31)
PATHOGENESIS
The pathogenesis of erythroderma/exfoliative dermatitis is unclear.
Currently, it is believed that the condition is secondary to an intricate
interaction of cytokines and cellular adhesion molecules, including
interleukins-1, 2, and 8, intercellular adhesion molecule-1 (ICAM-1) and
tumor necrosis factor (TNF).(10)
These interactions result in a dramatic increase in the epidermal
turnover rate, causing a higher than normal mitotic rate and an increase in
the absolute number of germinative skin cells. Furthermore, the time
required for cells to mature and travel through the epidermis is decreased,
and is manifested as an increased loss of epidermal material, together
with a significant loss of protein and folate.(40)
Consequently, scales consist of material normally retained by the
skin (nucleic acids, amino acids, soluble protein), and the daily loss of
scales increases from 500-1000 mg to 20-30gm(41,42). Despite this, the lost
material usually has marginal metabolic significance. Abel et al (43)studied
the immunophenotypic characteristics of benign (psoriasis, dermatitis,
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drug-induced) and malignant (Sezary syndrome, mycosis fungoides)
forms  of  erythroderma,  and  found  them  to  be  similar.  In
immunohistochemical studies conducted by Sigurdsson et al(44,45) the
dermal infiltrate in patients with Sezary syndrome mainly showed a
T-helper-2 cytokine profile, while benign reactive erythroderma showed a
T-helper-1 cytokine profile, indicating that, although clinically similar,
they have different underlying pathogenic mechanisms.
CLINICAL FEATURES
 Onset of erythroderma may be acute or insidious. It is
characterized by universal erythema and scaling involving more than
90% of body surface area. Initially the patient may present with
erythematous patches which then progress to form generalised erythema.
 About 2 to 6 days after the onset of erythema, scaling begins
classically over the flexures initially which then generalise to involve
other body sites. The skin becomes dull red as scaling progresses.(46) In
acute process scales are large with a reddish hue and in chronic cases they
become small with dusky colour. ( 47, 48) When the scaling is universal, the
skin is bright red, hot and dry. The intensity of erythema may fluctuate
over  a  period  of  few  days.  The  skin  is  relatively  dry  and  there  may  be
areas of crusting with moist lesions due to secondary infections.
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 In chronic cases edema and lichenification may be present causing
skin induration which may in turn lead to a sensation of tightness.
Chronic periorbital skin involvement may cause ectropion and epiphora.
 Palmoplantar keratoderma is common in erythroderma of chronic
duration, PRP, Norwegian scabies, idiopathic erythroderma and in
CTCL.(49,50) Pigmentary disturbances and eruptive seborrheic keratosis
may develop and as erythroderma subsides the keratosis may subside
spontaneously.(50)
 Other features like thermoregulatory disturbances, pruritus,
malaise, fatigue are reported by the patients commonly but these
symptoms are not specific to any cause.
HAIR CHANGES
Alopecia is seen in about 25% of patients. When the exfoliation
has been present for some time, the scalp and body hair may be lost. Hair
loss in chronic exfoliative dermatitis may be related to the diversion of
sulphur containing amino acid to synthesize the skin protein instead of
hair keratin.(51, 52)
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NAIL CHANGES
Nail changes that are described in erythrodermic patients are
discoloration, brittleness, dullness, paronychia, pitting, subungual
hyperkeratosis, Beau’s lines, shininess, onycholysis, onychauxis and
splinter hemorrhages.(3, 13) Shiny nails are indirect defect as patients rub
their hands on their skin to obtain relief from itching, preferring this to
actual scratching as this does less damage.(53) Shelley(54) described
alternating bands of nail plate discontinuity and leukonychia known as
shoreline nails in drug induced erythroderma reflecting the period of drug
intake. Nail changes may help to find out the underlying etiolgy. Hair loss
and nail changes will restore back to normal after clearing of the skin.
MUCOUS MEMBRANE
Mucous membranes are usually spared, but may be involved in
drug induced erythroderma. The types of mucousal lesions reported are
oral erosion, diffuse oral pigmentation, angular cheilitis, oral candidiasis,
geographic tongue, conjunctivitis, nasal erosions and crusting.(3,31)
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DERMATOPATHIC LYMPHADENOPATHY (LIPOMELANOTIC
RETICULOSIS)
Non specific lymphadenopathy occurs in exfoliative dermatitis
which is probably due to reaction to the inflammatory process in the skin
and is rarely of diagnostic or prognostic significance. However unusually
prominent or asymmetrical lymph node enlargement may suggest
lymphoma as a possible cause.(2,50) Commonly axillary, inguinal and
cervical group of lymph nodes are enlarged which are discrete, mobile,
non tender and have a firm rubbery consistency.(55) The presence of
palpable enlarged lymph nodes is common in cutaneous T cell
lymphoma. It is found in about one fourth of early cases, in 70% to 75%
of advanced cases and in 90% patients with generalized exfoliative
dermatitis that is with sezary syndrome.(56)
The pathogenesis of the lymphadenopathy is obscure, no definite
cause is established. Scratching induced by pruritus presumably brings
about the liberation of melanin from the epidermal cells, which is
transferred by the lymphatic vessels to the regional lymphnodes.
Biopsy study of the enlarged lymph nodes should be performed
for all patients in whom the etiology of the exfoliative dermatitis cannot
be determined. In the histopathological examination, the follicular pattern
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of the lymphnode will be retained in early stages. The follicles show
slight or moderate increase in their germinal centres surrounded by rim of
lymphocytes. The most conspicuous feature is enlarged paracortical area
due to presence of large number of macrophages and pale staining cells of
reticulum series. Within macrophages are aggregates of melanin, lipid
and rarely haemosiderin giving rise to the term ‘Lipomelanic Reticulosis’.
(57)
In series by pal and colleagues lymphadenopathy was present in
55.5% of cases and in all cases it was dermatopathic lymphadenopathy
except in one case where it was Hodgkin’s lymphoma, in a study by
chaudhary and colleagues 17 lymph node biopsy was done of which 33%
cases showed dermatopathic lymphadenopathy and incidence in other
studies was 21.3%,(26) 33%,(15) 22.67% (19) of cases.
HEPATOMEGALY
It is most commonly seen in drug induced erythroderma.
Hepatomegaly  was  seen  in  8%  of  the  cases  in  a  study  by  Sudho  and
colleagues.(39) Other studies have shown incidence of 25.5%,18%
13.33%,19.14%,15% and 2.5% of the cases.(9) Fulminant hepatitis has
also been reported in a few cases.
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SPLENOMEGALY
It is a rare finding in erythroderma and is most commonly
associated with lymphoma. Splenomegaly was demonstrated in 8 % of
cases in a study by Sudho and colleagues(39),  20%  and  14%  of  cases  in
another study.(28) Lymphadenopathy along with organomegaly is
suggestive of either malignancy or drug hypersensitivity.(12)
GYNAECOMASTIA
It is a common finding in almost all patients with exfoliative
dermatitis of at least several weeks (longer than 6 weeks). It is apparently
a hormonally mediated change although the precise mechanism is still
unknown. Schuster and Brown in 1962 reported gynaecomastia
secondary to unexplained hyperestrogenism. It's overall significance and
incidence were unknown. Hyperestrogenism is seen by increased urinary
excretion of estrogens.(29, 58)
OTHER FEATURES
Some  studies  reported,  sparing  of  exfoliation  over  nose  and
paranasal area, and called it the "nose sign".(59,60,61) Satish Agarwal and
colleagues suggested that this may be due to more sun exposure of this
area, which might have some ameliorating effect due to its presumptive
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antimitotic action and frequently blowing or rubbing one's nose. Both of
these may help to remove the scale.(60) Pal and colleagues suggested that
it is due to decreased responsiveness of spared area.(3)
“Deck chair sign” has been described in which erythroderma spares
abdominal skin folds. This sign is classic for papuloerythroderma of
Ofuji, which has been reported in Japan and Europe. Elderly men are
affected with flat topped erythematous papules that coalesce into
erythroderma; with sparing of abdominal, axillary and inguinal folds.(62-65)
This sign is also reported in atopic dermatitis, psoriasis and idiopathic
erythroderma.(3)
Generally exfoliative dermatitis is viewed as an end stage process
where the identifiable features of the underlying disorder are lost. This is
true in many cases but continued clinical observation may reveal local
changes which are characteristic of the primary cause. (12)
There are also certain clinical signs of diagnostic importance which
are associated with some underlying disorders and not with others. The
distinctive clinical features of the primary disease that give rise to
exfoliative dermatitis are discussed.
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PSORIATIC ERYTHRODERMA
Psoriatic erythroderma may represent a generalized Koebner’s
reaction especially when precipitated by topical treatment. Psoriatic
exfoliative dermatitis evolves from two types of psoriasis; Chronic stable
form of psoriasis and unstable psoriasis. Chronic stable form of psoriasis
can gradually evolve by process of koebnerisation into erythroderma.
During exfoliation, psoriatic characteristics are retained and prognosis is
good. In case of unstable psoriasis, the onset of erythroderma may be
sudden and the characteristic feature of the disease is lost, patient is ill
and itching is severe.(14, 66)
The triggering factors of psoriatic erythroderma include withdrawal
of systemic steroids, excessive use of potent topical corticosteroids,
abrupt discontinuation of methotrexate, topical irritants such as tars,
dithranal, systemic medications such as antimalarials, lithium,
terbinafine, phototherapy burns, infections including HIV, pregnancy,
emotional stress, hypocalcemia and systemic illness.(11,12,66) Classic
plaques of psoriasis vulgaris may be evident in early and remitting stages
of erythroderma. Psoriatic arthritis and psoriatic nail changes may be
present in some cases. Some times the typical nail changes of psoriasis
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persist but mostly there will be nail dystrophy which occurs in exfoliative
dermatitis.(12)
The various diagnostic clue to diagnose psoriasis as the underlying
cause include history of silvery scaly plaques in areas like elbow, knee,
scalp, lumbosacral area etc, nail changes like pits, subungual
hyperkeratosis, onycholysis, oil drop sign etc, association with psoriatic
arthritis and presence of collarette of scales suggestive of rupture of
pustules in case of pustular psoriasis.
ECZEMA
ATOPIC DERMATITIS
Past history of atopy and characteristic distribution pattern are
suggestive of the disease. Generalization of atopic dermatitis usually
follows exacerbation of chronic localized eczema of the anticubital,
popliteal fossae, face and neck. Pruritus is often severe, white
dermographism may be prominent. Atopic epicanthal fold of the lower
eye lid may be prominent. In chronic or severe atopic dermatitis, atopic
cataract may be apparent. Elevated level of IgE and eosinophilia is
common.(67)
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SEBORRHOEIC DERMATITIS
It has typical sites of predilection such as scalp, back of ears, alae
nasi, midline of chest and axilla. If patient gives history of preexisisting
skin lesion over the above mentioned areas seborrheic dermatitis can be
suspected.
CONTACT DERMATITIS AND STASIS DERMATITIS
 Various clues like distribution of original lesion, history of
contactants in case of contact dermatitis and history of pre existing
venous disease in case of stasis dermatitis may help in finding the cause.
It may generalise to produce erythroderma.
PHYTOPHOTODERMATITIS
In India the plant Parthenium hysterophorous belonging to
compositae family has been reported to produce erythroderma. The
sensitizer in this plant is sesqueterpene lactone.
PITYRIASIS RUBRA PILARIS
The classical adult type of PRP which characteristically progress in
a cephalocaudal direction is the most common type which may go in for
erythroderma over a period of 2-3 months. Persistence of islands of
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normal skin (Nappes Claires sign) with in exfoliated areas, follicular
horny papule present on dorsal aspect of the fingers, toes, knees and
elbows with waxy yellow diffuse palmoplantar keratoderma are the
clinical clues to an exfoliative dermatitis arising from pityriasis rubra
pilaris.(47) Pal and colleagues(3) suggested  that  the  islands  of  normal  skin
may simply reflect a less responsive skin in these particular areas.
IMMUNOBULLOUS DISORDER
In pemphigus vulgaris few bullae may be intact, moist, erosive or
crusted areas may be present due to rupture of bullae. Nikolsky's sign
may be positive. Tzanck smear from an intact bullae may show
acantholytic cells.(12, 55) In bullous pemphigoid there will be intense
pruritus, tense bulla, urticarial plaques and erosions. Nikolsky’s sign will
be negative and tzank smear may not show acantholytic cells. In
paraneoplastic pemphigus the patient may have recalcitrant oral lesions,
erythema multiforme like lesions and failure to thrive.
LICHEN PLANUS
It is an uncommon cause of erythroderma. The violaceous colour,
fine reticulate scale and angulation of the papule may be still present.
Oral, penile or vaginal mucosal lesions may reveal the characteristic lacy
white network pattern.(14,55)
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NORWEGIAN SCABIES
This condition has been commonly seen in senile and mentally
retarded patients, patients with poor cutaneous sensation (like leprosy,
syringomyelia and tabes dorsalis), and patients with severe systemic
disease (like leukaemias and diabetes) and in immunosuppressed
patients.(68)
Clinically itching may be minimal or absent with marked crusting
of hand and feet, subungual horny debris, erythematous scaly plaques
occurring on neck, scalp and trunk. This may become generalized. There
will be associated lymphadenopathy and eosinophilia. Mites can be easily
demonstrated under microscopy on examination of the scales or crust
with KOH preparation.(14,69)
DERMATOPHYTOSIS
Erythroderma has rarely been produced by chronic infection with
Trichophyton violaceum.(70) Dissemination of mycotic process may be
favoured by prolonged use of steroids, advancing age and focal infection.
DRUGS
A significant proportion of cases of erythroderma are due to drugs.
Patients are frequently on a plethora of drugs making delineation of
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etiological agent difficult. It should be remembered that topical drugs
may also cause contact dermatitis related erythroderma.(9) Patients with
erythroderma secondary to drug hypersensitivity syndrome appear toxic
and develop systemic manifestations such as fever, leukocytosis with
eosinophilia, edema, lymphadenopathy, organomegaly, liver dysfunction
and renal dysfunction. Onset is usually rapid and resolution is faster when
compared to erythroderma due to other causes. Exception to this is
hypersensitivity reactions to drugs like allopurinol, anticonvulsants and
antibiotics and this usually develops 2 to 5 weeks after starting drug
therapy and may persist for weeks despite discontinuation of the drug.(7,12)
Time of onset  is  variable as with gold and allopurinol  in which case the
eruption may occur after months or years. There are no special clinical
signs to indicate that drugs are the cause of exfoliative dermatitis. But the
ingestion of suspected drugs prior to the onset may be helpful. Usually it
is of acute onset with fever and erythema which may appear first in the
flexures then spread diffusely. Rash is of generalized eczema or
scarlatiniform or morbilliform erythema, symmetrical in distribution
associated with pruritus and oedema.(71) Oral lesions are common.(11,14,72)
Morar(73) identified adverse drug reactions to antituberculosis medication
as the most common cause of erythroderma in HIV-seropositive South
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African patients. The list of drugs causing erythroderma is ever
expanding hence it is important to consider all drug exposures.(50,74)
DAPSONE SYNDROME
Dapsone syndrome usually occurs four to five weeks
after initiation of therapy. It is a hypersensitivity reaction and is
not dose related.(75) The patient will present with erythroderma,
generalised lymphadenopathy, hepatosplenomegaly, fever and
methhaemoglobulinemia. They recover with omission of the drug and
treatment with topical emollient and systemic steroids.(76,77,78)
ICHTHYOSIS
Autosomal recessive congenital ichthyosis (ARCI) includes several
severe subtypes including harlequin ichthyosis (HI), lamellar ichthyosis
and non-bullous congenital ichthyosiform erythroderma. Patients with
these severe types of ichthyosis frequently show severe hyperkeratosis
and  scales  over  a  large  part  of  the  body  surface  form  birth  and  their
quality of life is often severely affected. Recently, research into the
pathomechanisms of these severe congenital ichthyosis have advanced
dramatically and led to the identification of several causative genes and
molecules underlying the genetic defects. The causative genes are
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transglutaminase 1 gene (TGM1), ABCA12, two lipoxygenase genes,
ALOXE3 and ALOX12B and ichthyin. (79,80)
SEZARY SYNDROME
Sezary syndrome is regarded as an erythrodermic, leukaemic
variant of cutaneous T-cell lymphoma. It is characterized by generalized
exfoliative dermatitis with intense itching, peripheral lymphadenopathy,
and the presence of sezary cells in the cellular infiltrate of the skin and in
the peripheral blood.(56)
The pre-sezary condition is defined as a chronic, steroid
unresponsive erythroderma, lymphadenopathy, lymphocytic band at
dermoepidermal junction and fewer than 1000 circulating sezary cells per
cu mm.(81) Sezary syndrome is characterised by generalised erythroderma,
associated with severe pruritus, palmoplantar keratoderma,
lymphadenopathy, organomegaly and circulating sezary cells greater than
1000/cu mm. In pre-sezary, there is no abdominal organomegaly and
lymphnodes reveal dermatopathic lymphadenopathy whereas in Sezary
abdominal organomegaly is present and cortical and paracortical
lymphnodes are infiltrated by variable number of Sezary cells along with
abnormal lymphocytes.(82,83) Palmoplantar keratoderma, alopecia and
onychodystrophy are progressive in Sezary syndrome. Low intermittent
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levels of circulating sezary cells is also seen in cases of extensive eczema,
psoriasis, atopic dermatitis and other inflammatory dermatitis.(84)
The dermal infiltrate in patients with Sezary syndrome mainly
shows a T- helper 2 (Th2) cytokine profile, this in contrast to T-helper 1
(Th1) cytokine profile in benign reactive erythroderma. This indicates
that although a relative uniform clinical picture of erythroderma is
obvious, different pathomechanisms may be underlying.(44)
ERYTHRODERMIC CUTANEOUS T-CELL LYMPHOMA
It may occur in many ways (a) By coalescence of localized CTCL
lesions to universal exfoliative dermatitis, (b) By allergic reaction as
contact dermatitis or drug induced exfoliative dermatitis superimposed on
CTCL, (c) By irritation with therapy or ultraviolet light. Such
erythrodermic T cell lymphoma have a poorer prognosis than localized or
generalised plaque T cell lymphoma.(81,85)
Patients with erythrodermic cutaneous T-cell lymphoma often have
markedly depressed levels of normal blood T cells, to the range seen in
advanced acquired immunodeficiency syndrome.(85)
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LYMPHOMA AND LEUKAEMIA
Pruritus is often severe and exfoliation is universal with infiltration
of skin and when it is severe that it can lead to leonine facies.
Lichenification is a common feature. Small rounded or annular patches of
skin may be spared which is an inconsistent but valuable diagnostic
sign.(14,55) Large asymmetrical lymph node enlargement with specific or
non specific histological changes, hepatosplenomegaly and raised ESR
may be the associated features.(2) Clues for internal malignancy causing
exfoliative dermatitis are
? Insidious development of exfoliative dermatitis.
? Progressive debility.
? Resistance of exfoliative dermatitis to the standard treatment
? Absence of prior skin disease. (86)
IDIOPATHIC VARIETY / “THE RED MAN SYNDROME”
The percentage of cases of idiopathic variety can be decreased with
detailed examination, observation and laboratory investigations, but in
any  series  of  cases  it  is  rarely  below  10%.  The  cutaneous  finding  may
precede  any  other  evidence  of  lymphoma  by  many  months  or  years.  If
those case are excluded the hard core of chronic exfoliative dermatitis of
idiopathic variety consists mainly of elderly men, in whom the condition
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runs a very long course with partial and temporary remissions. Pedersen
and colleagues described patients with exfoliative dermatitis in whom the
underlying cause could not be established as Redman syndrome, which is
associated with palmoplantar keratoderma, dermatopathic
lymphadenopathy, raised of serum IgE, non-specific skin histology or
some pleomorphic infiltration and exfoliative dermatitis extending over
one month.(14,87) It  is  occasionally  referred  to  as  "I  homme  rouge".  The
three most common cause of protracted idiopathic erythroderma are
probably atopic eczema of the elderly, intake of drugs overlooked by the
patient and prelymphomatous eruptions.
CAUSES OF NEONATAL AND INFANTILE ERYTHRODERMA
(88,89,90)
Infections
Staphylococcal scalded skin syndrome
          Toxic shock syndrome
Generalized congenital and neonatal candidiasis
Staphylococcal pustulosis
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Ichthyoses
Non-bullous ichthyosiform erythroderma
Bullous ichthyosiform erythroderma
Harlequin ichthyosis
Lamellar ichthyosis
Conradi-Hunnerman syndrome
Netherton’s syndrome
Immunodeficiency syndromes
Omenn’s syndrome
Graft versus host reaction
Hypogammaglobulinemia
Di George's syndrome
Severe combined immunodeficiency
Cutaneous T-Cell lymphoma
Metabolic disorders
Disorders of  biotin metabolism
Essential fatty acid deficiency
Others
Atopic dermatitis
Infantile seborrheic dermatitis
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Psoriasis
Pityriasis rubra pilaris
Diffuse mastocytosis
Protein malnutrition
Holocarboxylase deficiency
Acrodermatitis enteropathica
Leiner’s disease
Protein malnutrition
Pruszkowski A et al had studied 51 cases who presented with
erythroderma during their first year of life. The underlying causes
observed were immunodeficiency (30%), simple or complex
ichthyosis(24%), Netherton’s syndrome (18%), eczematous or
papulosquamous dermatitis(20%) and idiopathic(8%).(91)
The main complications were hypernatremic dehydration,
infections and failure to thrive. Erythroderma is a potentially life
threatening condition in infants.
The management of erythroderma, regardless of underlying cause
includes correction of caloric and protein intake, proper balance of oral
and parenteral fluids and electrolytes, and prevention and treatment of
infection.(89)
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ERYTHRODERMA IN HIV POSITIVE PATIENTS
The common causes of erythroderma in HIV patients are
1.  Psoriasis
2.  Seroconversion in HIV positive patients
3. Hypersensitivity to drugs
4.  Seborrhoeic dermatitis
5. Lymphoma
6.  Norwegian scabies
In a study done by Morar N et al(73) drug reaction was found to be
the commonest cause of erythroderma among HIV positive patients.
HISTOPATHOLOGICAL CLUES FOR THE DIAGNOSIS OF
ERYTHRODERMA(9,11,56,92)
Psoriasis
Epidermal hyperplasia, parakeratosis, neutrophils in cornified
layer, diminution or disappearance of the granular layer at least focally,
suprapapillary thinning, dilated and tortuous blood vessels that spiral up
within dermal papillae, superficial perivascular lymphohistiocytic
infiltrate and neutrophils in infiltrate.
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Cutaneous T- cell lymphoma
Perivascular or lichenoid infiltrate mainly composed of lymphoid
cells within papillary dermis. Presence of small or medium- sized
lymphocytes with irregular or convoluted nuclei. Epidermotrophism or
Pautrier’s microabscess. Wiry collagen bundles in haphazard array in the
papillary dermis.
Pityriasis rubra pilaris
Alternating orthokeratosis and parakeratosis (vertically and
horizontally), focal or confluent hypergranulosis, thick suprapapillary
plates, sparse superficial perivascular lymphohistiocytic infiltrate and
dialated non tortuous capillaries in the dermis
Drug induced erythroderma
Vacuolar alteration of basal keratinocytes. Scattered necrotic
keratinocytes along the basal layer and/or above it. Perivascular or
lichenoid lymphohistiocytic infiltrate involving dermal-epidermal
interface
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Dermatitis (eczema)
Moderate or prominent suprapapillary spongiosis, parakeratosis,
edema of papillary dermis and perivascular superficial lymphohistiocytic
infiltrate with many eosinophils.
Pemphigus
Subcorneal bulla and acantholytic keratinocytes.
Bullous pemphigoid
Subepidermal bullae with eosinophilic infiltrate.
Actinic reticuliod
Hyperkeratosis, acanthosis and atypical mononuclear cells admixed
in the superficial and deep dermal infiltrate with or without spongiosis.
Dermatophytosis
Hyphae within stratum corneum, mounds of parakeratosis.
Scabies
Scabetic mite in the stratum corneum. Perivascular and interstitial
infiltrate of eosinophils.
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Seborrheic dermatitis
Spongiotic psoriasiform dermatitis with parakeratosis often with
neutrophils at the tips of follicular ostia.
Dermatomyositis or subacte lupus erythematosis
Interface dermatitis with vacuolar alteration, often thickening of
the basement membrane, colloid bodies, and increased dermal mucin.
Sarcoidosis
Non caseating epitheloid dermal granulomas with little or no
mantle of surrounding lymphocytes.
Lymphoproliferative diseases
Superficial, deep and interstitial dermal infiltrate of atypical
mononuclear cells.
Source of major concern is exocytosis that characterizes the pattern
of  early  psoriasis  and  basal  epidermotropism  of  early  CTCL.  In  such
cases clues to the diagnosis are (i) the numerous lymphocytes and scanty
spongiosis in CTCL whereas, in psoriasis lymphocytes are usually sparse
(ii) marked edema of papillary dermis in psoriasis but usually not in
CTCL, atypical lymphocytes within the dermis and epidermis in CTCL
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but not in psoriasis (iii) the lichenoid arrangement of the dermal infiltrate
mostly composed of lymphocytes in CTCL but not in psoriasis.(92)
COMPLICATIONS OF ERYTHRODERMA (11-14,47)
1) Fluid and electrolyte imbalance
2) Hypoalbuminemia
3) Thermoregulatory disturbance
4) High output cardiac failure
5) Capillary leak syndrome
6) Infection
7) Acute respiratory distress syndrome
8) Gynecomastia
9) Metabolic disturbance
10) Hematological disturbance
11) Dermatogenic enteropathy
Management
Hospitalisation is a must with skilled nursing care. The initial
management of erythroderma is the same regardless of etiology. This
should include replacement of nutritional, fluid and electrolyte losses.(12)
The environmental temperature must be carefully regulated. Local skin-
care measures should be employed, such as oatmeal baths as well as wet
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dressings to weeping or crusted sites followed by the application of bland
emollients and low-potency corticosteroids. (11) Known precipitants and
irritants should be avoided and underlying cause, with its complications,
are to be treated.(12,13,72) Secondary infections are treated with antibiotics.
Heng(93) has suggested that colonization of skin by Staphylococcus aureus
may cause erythroderma, which will clear with appropriate antibiotics.
Antihistamines can be added if the patient has itching. Edema in
dependent areas, such as in periorbital and pedal areas, may require
diuretics.(11) Hemodynamic or metabolic instability should be treated
adequately. Serum protein, electrolyte and blood urea levels should be
monitored. This condition may resist therapy until the underlying cause is
treated; hence it is important to determine the underlying etiology early in
its management.(11,94,95)
COURSE
 The disease course is greatly influenced by the etiology.  It is
rapidly progressive when due to drug allergy, lymphoma, leukemia,
contact allergens or staphylococcal scalded skin syndrome. A slower
course  is  observed  if  from  a  primary  skin  disease  such  as  psoriasis  or
atopic dermatitis.(9,12,13,29) Drug-induced erythroderma patients recover
completely with prompt diagnosis and treatment.(12,13) The outcome is
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unpredictable in idiopathic erythroderma, and its course is marked by
multiple exacerbations.(13,72)
PROGNOSIS
Prognosis of erythroderma depends on the underlying disease
process. If the cause can be removed or corrected, the prognosis is
generally very good. If erythroderma is the result of a generalised spread
of a primary skin disorder such as psoriasis or dermatitis, it usually clears
with appropriate treatment of the skin disease but may recur at any time.
In case of drug induced erythroderma the duration of the disease process
is short lived, resolving once the offending drug is stopped. If
erythroderma is due to unknown cause the course is often unpredictable
with multiple episodes of remissions and exacerbations.(11)
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AIMS & OBJECTIVES
(1)  To study the incidence of erythroderma in relation to age and
sex.
(2)  To study the etiology, clinical features & course of the
disease.
(3)  To study the histopathology in relevant cases.
(4)  To study the metabolic and systemic complications.
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MATERIALS AND METHOD
The study was conducted among individuals attending the
outpatient dermatology clinic as well as the inpatients of the dermatology
ward of Rajiv Gandhi Government General Hospital, Chennai during the
period October 2010 - September 2012. All new cases of erythroderma of
both sexes and of all age groups who attended the dermatology clinic
during the said period, were taken for this study.
METHOD OF COLLECTION
A  total  of  65  patients  of  erythroderma  were  selected.  It  is  a
prospective observational study. The cases were analysed in detail as
follows. All patients erythema and scaling involving more than 90% of
the body surface area as calculated by Wallace’s rule of nine were
enrolled in the study in accordance with the definition of erythroderma.
 A detailed history was recorded and a through clinical examination
was performed for each patient. At first, preliminary data in the form of
age, sex, occupation etc were noted. Then a detailed history regarding
onset, evolution, duration, symptoms, previous skin disease or drug
intake were noted. Any history of recurrence and precipitating factors like
drugs, topical applications and infective episodes prior to onset of disease
were also noted.
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I. Each patient was examined and the following details were noted:
Type of scales
Sizes of scales
Color of scales
Associated lichenification / fissuring
Ectropion, eclabion
Pedal edema
Examination of scalp for scales, hair loss
Examination of nails and mucosa
Associated arthritis
Specific signs like sparing of flexures and nose sparing sign.
II. The following investigations were carried out -
Haematological investigations:
Haemoglobin percentage
Total and differential leucocyte count
Erythrocyte sedimentation rate
Peripheral smear study
Platelet count
Biochemical investigations:
Blood sugar and urea
Serum creatinine
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Serum electrolyte
Serum calcium and uric acid
Total proteins, albumin globulin ratio
Other investigations:
Chest X ray
Motion for occult blood
USG abdomen
ECG
Blood VDRL
Skin biopsy
Scraping for fungus and Acarus mite, lymph node biopsy, Tzanck
test, direct immunofluorescence, patch test and HIV ELISA were done in
selected cases. In adults, per rectal examination was carried out to detect
underlying malignancy. The course and duration of the disease was
studied and episodes of recurrence were noted.
The patients who were hospitalized were given supportive
treatment along with systemic steroids in deserving cases, which was
withdrawn gradually and later specific treatment was instituted for the
underlying dermatoses.
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OBSERVATIONS & RESULTS
In the two year study period, 65 patients were diagnosed as
erythroderma in our department. Various observations made are as
follows.
INCIDENCE
Between the period Oct 2010 - Sep 2012, 217551 patients attended
the OPD department. Among them, 65 patients were diagnosed as
erythroderma and the incidence of erythroderma during the period was
0.029%
Table No.1: Incidence of erythroderma
Study period Total No.ofpatients
No.of cases of
erythroderma Percentage
Oct 2010 - Sep 2012 217551 65 0.029
AGE DISTRIBUTION
 Age of the patients ranged from 50 days to 71 years with the
average age being 40.25 years. Maximum number of patients belonged to
the age group of 50-59 years (21.53%).
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Table No.2: Age distribution of erythroderma
Patient’s age Number (n=65) Percentage
0-9 9 13.84
10-19 5 7.69
20-29 8 12.30
30-39 8 12.30
40-49 9 13.84
50-59 14 21.53
60-69 11 16.92
70-79 1 1.53
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SEX DISTRIBUTION
 Among 65 patients, 44 were male (67.69%) and 21 were female
(32.30%), male to female ratio being 2.1:1 showing a male
predominance.
Table No.3: Sex distribution of erythroderma
Sex No.of cases (n=65) Percentage
Male 44 67.69
Female 21 32.30
Male-67.69%
Female-32.30
SEX DISTRIBUTION
Male
Female
50
ONSET
Majority (58.46%) of patients had insidious onset of erythroderma,
41.53% of patients had sudden onset.
Table No.4: Onset of the illness
Onset No.of cases (n=65) Percentage
Sudden 27 41.53
Gradual 38 58.46
Sudden-41.53%Gradual-58.46%
ONSET
Sudden
Gradual
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SYMPTOMS
 All the patients had generalized erythema involving more than
90% of their body surface area and various degrees of scaling. Itching,
the most common complaint, was recorded in 42 patients (64.62%).
Fourty patients (61.54%) had complaints of malaise, thirty one patients
(47.69%) had chills and eighteen patients (27.69%) had fever. Only two
patients (3.07%) in the study had oliguria. None of the patients
complained of loose stools suggestive of dermatogenic enteropathy.
Table No.5: Frequency of presenting complaints
Symptoms No.of cases Percentage
Itching 42 64.62
Scaling 65 100
Redness 65 100
Chills 31 47.69
Malaise 40 61.54
Fever 18 27.69
Oliguria 2 3.07
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PHYSICAL EXAMINATION FINDING
Nail changes were seen in 45 patients (69.23%). They were
commonest in cases of psoriatic erythroderma. Twenty nine
patients(44.61%) had eye involvement in the form of conjunctival
congestion, ectropion and icterus. Mucosal involvement was seen in 6
patients (9.23%).
 Most  of  the  patients  had  involvement  of  scalp  in  the  form  of
exfoliation. Fifteen patients (23.07%) had diffuse alopecia. One patient
had tinea amiantacia and 5 patients (7.69%) had psoriatic corona.
 Involvement of palms and soles was seen in 26 patients (40%). Six
patients (9.23%) had palmoplantar keratoderma. Among them two had
pityriasis rubra pilaris, two had psoriasis, one had idiopathic
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erythroderma and one had malignancy induced erythroderma. Four
patients (6.15%) had instep involvement. Crusting of palms and soles was
seen in a patient with Norwegian scabies.
 As far as the systemic features are concerned 18 patients (27.69%)
had increased temperature (>38oC), 17 patients (26.15%) had pallor, 21
patients (32.30%) had lymphadenopathy, 2 patients (3.07%) had
hepatosplenomegaly and 26 patients (40%) had significant pitting pedal
edema.
NAIL CHANGES
 Forty five patients (69.23%) had nail changes. Ridging of the nail
was the most common change, which was seen in 17 patients (26.15%).
Other nail findings observed were pitting (16.92%), subungual
hyperkeratosis (18.46%), onychodystrophy (13.84%), Beau’s lines
(12.30%), onycholysis (9.23%), shiny nails (9.23%), onychomadesis
(6.15%) and nail discoloration (9.23%).
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Table No.6: Nail changes in erythroderma
Nail changes No.of cases Percentage
Pitting 11 16.92
Ridging 17 26.15
Onycholysis 6 9.23
Subungual hyperkeratosis 12 18.46
Onychodystrophy 9 13.84
Shiny nails 6 9.23
Beau’s line 8 12.30
Onychomadesis 4 6.15
Nail discoloration 6 9.23
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EYE INVOLVEMENT
Eye changes were seen in 29 patients (44.61%). Fourteen patients
(21.54%) had ectropion among whom three had lamellar ichthyosis.
Eleven patients (16.92%) had conjunctival congestion. One patient
(1.53%) with Dapsone syndrome had icterus and two patients (3.07%)
had Dennie Morgan fold.
Table No.7: Frequency of eye changes in erythroderma
Eye changes No.of cases Percentage
Ectropion 14 21.54
Conjunctival congestion 11 16.92
Icterus 1 1.53
Dennie Morgan fold 2 3.07
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PEDAL EDEMA
 It  was  seen  in  a  26  patients  (40%).  The  edema  was  bilateral,
pitting and non tender. One patient had bilateral elephantiasis due to
filariasis.
LYMPHADENOPATHY
 Lymphadenopathy was seen in 21 patients (32.30%). The
commonest nodes affected were inguinal and axillary nodes. None of the
patients had cervical lymphadenopathy. Enlarged lymphnodes were firm,
mobile and discrete. One patient with non Hodgkin’s lymphoma had
enlarged axillary and inguinal nodes.
HEPATOSPLENOMEGALY
 It was noted in 2 patients (3.07%). One patient had non Hodgkin’s
lymphoma and the other patient was a case of dapsone syndrome.
GYNAECOMASTIA
 Gynaecomastia was seen in two patients (3.07%). None of them
showed any underlying liver pathology or testicular atrophy. Five patients
(7.69%) showed macrothelia.
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Scales were grayish white or white in color and non adherent in
most of the cases. Adherent moist scales and crust were seen in a patient
with pemphigus foliaceous. In two patients with lamellar ichthyosis, the
scales were large plate like, dark colored and adherent. Nose sign, that is
sparing of nose of erythema and scaling was seen in 8 patients (12.30%).
 In about 13 patients (20%), the erythema and scaling over the face
was less compared to other body parts (relative sparing of face). Sparing
of abdominal folds (Deck chair sign) was seen in 7 cases (10.76%). Four
of  them  had  psoriasis  while  three  had  eczema.  Islands  of  normal  skin
(Nappes claires sign) was seen in two patients (3.07%). Both the patients
had erythrodema with pityriasis rubra pilaris as the underlying
dermatological condition. Two children with lamellar ichthyosis had
eclabion and hypoplastic ears. Oral mucosal involvement in the form of
congestion and erosion was seen in 6 patients (9.23%) and all the 6 cases
were drug induced erythroderma.
58
Table No.8: Physical examination findings among the patients
Physical examination No.of cases Percentage
Nail changes 45 69.23
Eye changes 29 44.61
Palms & soles involvement 26 40
Hair loss 15 23.07
Mucosal involvement 6 9.23
Pallor 17 26.15
High temperature 18 27.69
Lymphadenopathy 21 32.30
Hepatosplenomegaly 2 3.07
Pedal oedema 26 40
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Final diagnosis was the result of evaluation of the clinical,
biochemical, histiological findings and of the evolution of erythroderma
along with history given by the patients in each individual case.
ETIOLOGICAL CAUSES
Etiologically patients were categorized into four groups:
The first group comprised of pre existing dermatoses (40 patients,
61.53%): psoriasis, 20 (30.76%); eczema, 11 (16.92%); ichthyosis,
4 (6.15%); pemphigus foliaceous, 2 (3.07%); PRP, 2 (3.07%); and
crusted scabies, 1 (1.53%). Among the patients with pre existing
dermatoses, psoriasis was the most common cause followed by eczema.
The second group, which comprised of drug induced erythroderma,
had 17 (26.15%) patients. Carbamazepine was the most common
etiological agent in 5 patients followed by native medicine in 3 patients,
anti retroviral therapy in 2 patients, sodium valproate, antituberculous
drugs, dapsone and ofloxacin in 1 patient each. In the remaining three
patients the nature of the drug could not be found out. Relationship
between a drug and erythroderma was established from the history of
antecedent intake of the incriminating drug preceding the onset of
erythroderma and clearing of the manifestations following withdrawal of
the drug.
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 The third group comprised of malignancy associated erythroderma
(1 patient, 1.53%).
 The last group was idiopathic, which comprised of 7(10.76%)
patients, with no specific history, associated factor or specific histology.
Table No.9: Etiology of erythroderma
Underlying cause No.of cases (n=65) Percentage
Pre existing dermatoses
 Psoriasis
 Eczema
 Ichthyosis
 Pemphigus foliaceous
 PRP
 Crusted scabies
40
20
11
4
2
2
1
61.53
30.76
16.92
6.15
3.07
3.07
1.53
Drugs 17 26.15
Malignancy 1 1.53
Idiopathic 7 10.76
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LABORATORY INVESTIGATIONS
Low haemoglobin was seen in 17 patients (26.15%), increased
ESR was seen in 20 patients (30.76%), hypoproteinemia was seen in
8 patients (12.30%), eosinophilia was seen in 8 patients (12.30%),
atypical lymphocytes in peripheral smear was seen in one patient (1.53%)
with non Hodgkin’s lymphoma induced erythroderma. Five patients
(7.69%) had altered liver function test and all of them had drug induced
erythroderma. One patient (1.53%) had increased serum creatinine.
Tzank smear positivity was seen in two patients of pemphigus
foliaceous. In a patient with crusted scabies, acarus mite was
demonstrated by scrapping. Patch test with parthenium was positive in
6 patients and with potassium dichromate in 1 patient. USG abdomen
ETIOLOGY
Psoriasis
Eczema
Ichthyosis
Pemphigus foliaceous
PRP
Crusted scabies
Drugs
Malignancy
Idiopathic
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revealed hepatosplenomegaly in a case of non Hodgkin’s lymphoma and
Dapsone syndrome.
SKIN BIOPSY
 Histopathological examination of the skin biopsy was performed
in 53 patients (81.53%) under local anesthesia. Skin biopsy was not
performed in some of the cases because the cause of erythroderma was
clear from the start. Skin biopsy was performed in all the cases classified
as malignancy and idiopathic. The biopsies were often performed within
the first three days after the patients were admitted in the hospital.
Among  the  53  patients  in  whom  the  biopsy  were  done,  the
histopathological diagnosis was consistent with the clinical diagnosis in
23 (43.39%) patients.
 In about 17 cases of psoriatic erythroderma, biopsy showed
histopathological features like hyperkeratosis, parakeratosis, regular
acanthosis, suprapapillary thinning and dilated dermal blood vessels with
inflammatory infiltrate. Spongiform pustules of kogoj was present in
about 9 cases only.
 Drug reactions did not show any characteristic features except in
one patient whose skin biopsy showed eosinophilic infiltrate in the
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dermis. In case of the pemphigus foliaceous and PRP histopathology
showed characteristic features of the disease.
 In case of non Hodgkin’s lymphoma skin biopsy showed non
specific inflammatory infiltrate in upper dermis.
LYMPH NODE BIOPSY
 Out of the three lymph node biopsies performed, one revealed
features of non Hodgkin’s lymphoma. The other two cases showed
retained follicular architecture, enlarged paracortical area and
melanophages in plenty suggestive of dermatopathic lymphadenopathy.
COURSE
The group associated with best prognosis was that related to drugs,
who improved dramatically after stopping of the offending drug along
with supportive measures. Patients with psoriatic erythroderma responded
well with complete resolution of erythema and scaling. The other patients
with pemphigus foliaceous, crusted scabies and PRP also respond well
with therapy. Patients with lymphoma and ichthyosis did not show good
response with treatment.
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Recurrence was noted among 9 patients (13.84%) during the study
period of which 3 were erythroderma of unknown etiology and 6 were
psoriatic erythroderma. During the study period two patients with
erythroderma died. One was due to non Hodgkins lymphoma and the
other was a case of pustular psoriasis.
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FIG 1. A case of psoriatic erythroderma with relative sparing of face
FIG 2- Chronic plaque type psoriasis going in for erythroderma
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(A)
(B)
FIG 3 A & B – Erythema, scaling and pustules in a case of pustular psoriasis
FIG 4 – Psoriatic erythroderma with pityriasis amiantecea
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(A)
(B)
FIG 5: (A) & (B) Crusting and superficial erosions in pemphigus foliaceous
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FIG6: PRP showing follicular papules and islands of normal skin
FIG 7:  Phytophotodermatitis with FIG 8 : Air born contact dermatitis
             Denny morgan folds
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(A)                                                        (B)
(C)
FIG 9 : Lamellar ichthyosis – (A&B) showing ectropion, eclabion
(C) showing plate like scales
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FIG 10: Dapsone syndrome with icterus
FIG 11: Drug induced erythroderma
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FIG 12: Nail changes
Twenty nail dystrophy
    Onycholysis & Leuconychia Nail discoloration
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                       Beau’s line                                                     Onychomadesis
Pitting                                         Subungual hyperkeratosis
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(A)
(B) PRP sandal – yellow waxy keratoderma
(C) Palmoplantar keratoderma with fissures
FIG 13: (A), (B) & (C) Palmoplantar keratoderma
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FIG 14:  Instep involvement in psoriasis
FIG 15: Peeling of skin over the soles in drug induced erythroderma
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FIG 16: Nose sparing sign
FIG 17: Sparing of abdominal folds
FIG 18: Macrothelia
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FIG 19: Geographic tongue
FIG 20: Conjunctival  congestion
FIG 21: Bilateral pedal edema
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                                 (A)
       (B)
FIG 22  (A) A case of psoriatic erthroderma with diffuse hair loss
              (B) Same patient with complete regrowth of hair after recovery
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                                (A)
     (B)
(C)
         (D)
FIG 23: (A), (B), (C) & (D) Norwegian scabies
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(A)     (B) Peripheral smear shows leucocytosis
(C) High power shows lymphoblast         (D) Lymph node biopsy shows loss of
                architecture and infiltrated with
                                                                            atypical lymphoid cells
(E)  Immunohistochemical stain positivity with CD-20
FIG 24: (A), (B), (C), (D) & (E) Non Hodgkin’s lymphoma
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FIG 25: Patch test  positive for parthenium
(A)
(B)
FIG 26 (A & B): Psoriasis. Regular acnthosis and munro microabscess
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(A)
(B)
FIG 27(A & B): Pustular psoriasis. Large collections of neutrophils with
spongiosis in granular and upper spinous layer
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(A)
(B)
FIG 28 (A) & (B) : Non specific dermatitis. Mild lymphocytic infiltration seen in
dermis
FIG 29: Showing spongiosis in a case of eczema
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(A)
(B)
(C)
FIG 30: Pemphigus foliaceus
(A) A subcornial bullae with acantholytic cells and neutrophils in cavity
(B) Acantholytic cell in tzank smear
(C) The intercellular IgG deposits in intercellular space of epidermis
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DISCUSSION
The diagnosis of erythroderma was made based on morphology
and percentage of involvement of skin.
INCIDENCE
 In our study, the average annual incidence of erythroderma in
patients with skin diseases was 0.029 % attending our OPD. The
incidence of erythroderma noted in the study done by Sehgal &
Srivastava(9) in 1986 was 0.035%.
Table No.10: Incidence of erythroderma in various studies
Study Incidence
Sehgal & Srivastava(9) -1986 0.035 %
Present study 0.029 %
0
0.01
0.02
0.03
0.04
Sehgal & Srivastava Present study
Incidence
Percentage
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AGE & SEX INCIDENCE
 In the study, the maximum number of patients with erythroderma
were seen in the age group 50-59 (21.53%) followed by 60-69 (16.92%)
and 40-49 (13.84%).
 This is in concurrence with other studies, where the maximum
incidence was seen in 50-59 years of age group(3,27,96). The mean age of
the patient in the study being 40.25 years.
Table No.11: Mean age of erythroderma in various studies
Author Mean age
Bharatiya PR(27) et al 1995 40.93
Pal S(3) et al 1998 41.6
Akhyani M(26) et al 2005 46.2
Jowkar F(97) et al 2006 48.6
Munyao TM(98) et al 2007 47
Yuan XY(25) et al 2010 53.4
Hafeez J(96) et al 2010 47.8
Present study 40.25
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Previous studies have shown a male predominance with male to
female ratio approximately between 1.85:1 to 2.8:1. Our study also have
shown a male predominance with male to female ratio being 2.1:1.
Table No.12: Sex ratio of erythroderma
Studies Male to female ratio
Botella ER(35) et al 1994 2.8:1
Pal S(3) et al 1998 2.8:1
Leenutaphong V(38) et al 1999 2:1
Akhyani M(26) et al 2005 1.85:1
Jowkar F(97) et al 2006 1.9:1
Hafeez J(96) et al 2010 2.33:1
Present study 2.1:1
0
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20
30
40
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Mean age
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SEX RATIO
ONSET
 Our  study  showed  that  27  patients  (41.53%)  had  acute  onset  of
erythroderma. Among them 17 patients were drug induced erythroderma,
5 were psoriasis, 2 were phytophotodermatitis and one each of pemphigus
foliaceous, seborrheic dermatitis and idiopathic.
 Remaining 38 (58.46%) patients had a rather insidious onset with
a gradually progressing course. An acute onset was seen in 32% of
patients  in  a  study  done  by  Rafael  BE  et  al(28) and  69%  on  a  study
conducted by Pal S et al(3) .
0
0.5
1
1.5
2
2.5
3
3.5
4
FEMALE
MALE
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Table No.13: percentage of sudden onset of erythroderma in different
studies
Authors Percentage
Rafael BE, et al - 1994 32
Pal S, et al - 1998 69
Present study 41.53
CLINICAL FEATURES
 Irrespective of etiology, clinical features of erythroderma were
almost identical. Once the erythroderma is fully established it is difficult
to differentiate between various causes of erythroderma. Scaling and
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Rafael BE,et-1994 Pal S,et al-1998 Present study
gradual
sudden
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erythema was seen in all patients, in most cases it was erythema which
begins first followed by scaling over a period of 4-5 days. In acute cases
the scales were large and in chronic cases they were of small size.
 In our study, commonest symptoms were generalised scaling
(100%), redness (100%) followed by itching (64.62%), malaise (61.54%),
chills (47.69%), fever (27.69%) and oliguria (3.07%). None of the
patients had dermatogenic enteropathy. In studies done by Hafeez et al(96),
Akhyani M(26) et  al,  Yuan  XY (25)et al, Bandyopathyay D(31) et al, also
shown generalized scaling and erythema in upto 100% of cases.
 Hyperthermia was noted in 27.69% of patients. None of the
patients had hypothermia. The study by Pal and colleagues(3) had shown
hyperthermia in 40% and hypothermia in 5.5% of patients.
 Lymphadenopathy was seen in 32.30% of cases. Most commonly
inguinal lymph nodes were involved followed by axillary lymph nodes.
Lymph node biopsy was done in 3 patients, out of which 1 patient
showed features suggestive of NHL and other 2 patients showed features
of dermatopathic lymphadenopathy. In a study by Pal and colleagues(3)
lymphadenopathy was present in 55.50% of cases and all were
dermatopathic lymphadenopathy except in one case it was Hodgkin’s
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lymphoma. Other studies have shown lymphadenopathy ranging from
10% to 67.40%.(25,26,27,31,39,96,97)
 Pedal edema of pitting type was observed in 40% of cases. Pedal
edema has been reported in 14.4% to 78.67% of cases in various
studies.(25,26,27,31,39,96,97)
 Mucosal involvement was observed in 9.23% of cases in the form
of oral mucosal congestion and erosions. Other studies have shown
mucosal involvement ranging from 1% to 36.6% of cases.(3,25,26)
 Hepatomegaly was seen in 2 patients (3.07%). One patient had
NHL and the other had dapsone syndrome. Similar finding was seen in a
study done by Yuan XY and colleagues.(25)
 The “nose sign” of erythroderma was reported by Pavithran.(61) In
our study it was present in 31 cases(47.69%). The reason for this
phenomenon is not exactly known but it is suggested that it is either due
to greater exposure of nose to sunlight , with its presumptive anti mitotic
activity or the habit of frequent rubbing of nose leading to removal of
scales.
 In our study, deck chair sign was seen in 7 patients (10.76%). Pal
S and colleagues(3) had described this sign in 5.5% of their patients.
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 Hair  loss  was  observed  in  23.07%  cases  in  our  study.  It  was
observed  in  24% of  cases  in  a  study  by  Sudho and  colleagues(39) and in
30% of cases by Pal and colleagues(3)
 Nail changes was observed in 69.23% of cases. Most common nail
change was ridging of nails (26.15%) followed by subungual
hyperkeratosis (18.46%). The study done by Sudho and colleagues(39) had
shown pitting (24%) and onycholysis (24%) to be the most common nail
changes.
Table No.14: Nail changes in erythroderma
Nail changes Sudho et al(39) Present study
Pitting 24% 16.92%
Onycholysis 24% 9.23%
Beau’s line 20% 12.30%
Subungual hyperkeratosis 16% 18.46%
Ridges 16% 26.15%
Nail discolouration 12% 9.23%
Shiny nails 8% 9.23%
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Table No.15: comparison of clinical features of erythroderma in
various studies
Clinical
features
Hafeez
J(96)
et al
2010
Jowkar
F(97)
et al
2006
Akhyani
M(26) et
al 2005
Bharatiya
PR(27)
et al 1995
Yuan
XY(25)
et al
2010
Bhadyop
adhyay D
(31)et al
1999
Sudho
R(39) et
al 2003
Pal S(3)
et al
1998
Present
study
Scaling 100% 56.8% 100% 100% 100% 100% 100% 84.4% 100%
Redness 100% 100% 100% 86.95% 100% 100% 80% 100% 100%
Itching 96% - 97.5% - 93.9% - 80% - 64.62%
Chills - 30.3% - - 18.3% - 60% - 47.69%
Fever 30% 4.9% 33.6% - 37.8% - 32% 40% 27.69%
Nail
changes
40% 36.2% - 54.35% 336.6% 56% 64% - 69.23%
Eye changes - - - - - - 16% - 44.61%
Palms &
soles
- 8.8% - 39.13% - 29.33% - - 40%
Hair loss 8% 9.8% - - - - 24% 30% 23.07%
Mucosal
involvement
2% - 1% - - 2.66% 32% 36.6% 9.23%
Pallor 10% - - 80.43% - - - - 26.15%
Lympadeno
pathy
10% 18.6% 21.3% 67.40% 15.9% 22.67% 32% 55.5% 32.30%
Hepatosplee
nomegaly
4% 0.9% 4% 15.21% 3.6% 13.33% 8% 25.5% 3.07%
Pedal edema 14% 27.4% 14.4% 54.35% 25.60% 78.67% 36% _ 40%
0%
5%
10%
15%
20%
25%
30%
Sudho et al(39) Present study
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CLINICAL FEATURES
LABORATORY FINDINGS
 Hemoglobin  was  low  in  26.15%  of  cases.  In  a  study  by
Bandyopadhyay(31) and colleagues it was observed in 48% of cases and in
4.90% of cases in Jowkar F(97) and colleagues series.
 Eosinophilia was seen in 12.30% of cases which is similar to the
study by Bharatiya PR and colleagues.(27)
 Increased  ESR  was  seen  in  30.76%  of  cases  in  our  study.  In  a
study by Jowkar F and colleagues(97) it was observed in 20.58% of cases.
 Hypoproteinemia was observed in 12.30% of cases in our study
which  is  in  concurrence  with  the  study  done  by  Yuan  XY  et  al(25)
0% 20% 40% 60% 80% 100%
Scaling
Redness
Itching
Chills
Fever
Nail changes
Eye changes
Palms & soles
Hair loss
Mucosal involvement
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Lympadenopathy
Hepatospleenomegaly
Pedal edema
percentage in present study
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(13.4%). Increased serum creatinine was observed in 1.53% of cases.
None of the patient had significant electrolyte imbalance.
ETIOLOGY OF ERYTHRODERMA
 Psoriasis was the most common cause accounting for 30.76% of
cases. Similar findings were noted in studies done by Sudho et al(39)
(32%) and Bandyopadhyay et al(31)(33.33%). Diagnosis of psoriasis was
made on the basis of prior history of being treated for psoriasis, clinical
examination and histopathological correlation.
 Eczema as a cause of erythroderma was seen in 16.92% of cases
which is in concurrence with the study done by Bandhyopadyay and
colleagues (17.33%).(31)
 Ichthyosis as a cause was observed in 6.15% of cases. In a study
done by Pal S and colleagues(3) 7.8% of cases had ichthyosis as a cause of
erythroderma.
 PRP was  seen  in  3.07% of  cases,  which  was  correlating  with  the
study by Pal S and colleagues.(3)
 Pemphigus foliaceous as a cause was observed in 3.07%, which is
in concurrence with the study done by Sudho et al(39) (4%) and Hafeez
et al(96) (4%).
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 Crusted scabies was seen in 1.53% of cases, which was correlating
with the previous studies. (3,31,96)
 Drug reaction as etiology was seen in 26.15% of cases. Drugs
implicated were carbamazepine, native medicine, ART, ATT, sodium
valoporate, dapsone, ofloxacin and uncommon drugs which coincides
with the previous studies.(39,101) Most common drug that lead to
erythroderma was carbamazepine (5 out of 17 cases - 29.41%) as
described in study by Mapar MA and colleagues(101) (8  out  of  20  cases)
and Akhyani M et al (26) (12 out of 21 cases). A recent history of intake of
newer drug, sudden onset, peripheral eosinophilia and improvement of
the condition once the offending drug was withheld helped us for
implicating drug reaction as the etiology of erythroderma.
 Malignancy was seen in 1 patient (1.53%), the underlying
malignancy being NHL which was diagnosed by peripheral smear
examination and lymphnode biopsy. In various previous studies,
malignancy as a cause of erythroderma ranged from 2.9% to 29% of
cases.
 In 10.76% of cases, eiological factor for erythroderma could not
be determined inspite of thorough clinical and histopathological
examinations. The incidence of idiopathic erythroderma ranged from
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6.1% to 32% in various previous studies.(25,30,101) Repeated biopsies in two
patients did not yield any help in the diagnosis. The other patients did not
give consent for the same. It is imperative to have long term follow up
and to rule out cutaneous lymphoma as the cause.
Among the 53 patients on whom the biopsy was done, the
histopathology helped in correlating and confirming the diagnosis in
43.39% of cases, where as in study by Bandyopadhy and colleagues there
was correlation in 52% of cases.
Experience from the study supports the view that erythroderma
although a very disturbing disorder, does not pose a significant risk to the
patients life. The main challenge lies in identifying the underlying cause
and managing accordingly.
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Table No.16: Comparison of etiology of erythroderma in various studies
Study
Pre exsisting dematosis
Drugs Malignancy Idiopathic
Psoriasis Eczema Icthyosis P.F PRP N.S Others Total
Nicolis(100) and Helwig- 1973 - - - - - - - 25 42 21 12
Hasan (101)et al-1983 10 30 2 0 0 0 0 42 22 4 32
King LE(99) et al-1986 - - - - - - - 30 34 20 16
Botella ER(35) et al -1994 - - - - - - - 62.5 16 12.5 9
Bharatiya PR(27) et al-1995 - - - - - - - 67.40 21.74 4.35 6.51
Chaudhary(30)et al -1997 40 26.66 0 0 0 0 0 66.66 10 6.66 16.66
Pals(3) et al-1998 37.8 12.2 7.8 5.6 2.2 2.2 6.6 74.4 5.5 5.5 14.6
Bandyopadyay (31)et al-1999 33.33 17.33 1.33 5.33 5.33 1.33 0 63.98 12 2.67 21.33
Eugster R(36) et al-2001 - - - - - - - 58 16 11 16
Sudho(39) et al-2003 32 20 0 4 0 0 8 64 24 4 8
Rym(34) et al-2005 51.25 7.5 0 6.25 1.25 1.25 5 72.50 11.25 8.75 7.5
Akhyani M(26)et al-2005 27.8 19.6 1 1 8.2 1 1.2 59.8 21.6 11.3 7.2
Jowkar F(97)et al-2006 19.60 34.31 0 0 0.98 0.98 0 55.9 29.4 2.9 11.8
Hafeez(96)et al -2010 16 38 4 4 2 2 0 66 12 4 18
Yuan XY (25) et al-2010 - - - - - - - 72 17 4.9 6.1
Mapar MA (101)et al-2011 21.17 32.94 2.35 1.17 0 0 2.34 59.97 23.52 8.23 8.23
Present study 30.76 16.92 6.15 3.07 3.07 1.53 0 61.53 26.15 1.53 10.76
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Comparison of etiology of erythroderma in various studies
HISTOPATHOLOGICAL CORRELATION
 In  this  study  skin  biopsy  was  done  in  53  patients  and  the
histological findings were compared with the clinical diagnosis. Among
this 43.39% of biopsy section was rewarding in arriving at a diagnosis. In
various studies histopathological correlation ranged between 40.91% to
66.4%. (27,96,97)
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Table No.17: Histopathological correlation in various studies
Study Histopathological correlation
King LE et al-1986(99) 43%
Bharatiya PR et al-1994(27) 40.91%
Walsh NM et al-1994(102) 53%
Jowkar F et al-2006(97) 66.40%
Hafeez J et al-2010(96) 60%
Present study 43.39%
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SUMMARY AND CONCLUSION
After analysing 65 cases of erythroderma admitted in our hospital
during a period of two years the following observations were made;
? The average annual incidence of erythroderma among the
patients who attended the skin department of our hospital
was 0.029%.
? Maximum number of patients were in the age group 50-59
(21.53%) with a male to female ratio of 2.1:1
? The onset was acute in 41.53% and gradual in 58.46% of
cases.
? Itching (64.62%) was the most common symptom followed
by malaise (61.54%), chills (47.69%), pedal edema (40%),
palms & soles involvement (40%) and fever (27.69%).
? Lymphadenopathy was observed in 32.30% of cases.
? Hyperthermia was seen in 27.69% of cases, pallor in
26.15%, diffuse hair loss in 23.07% and hepatosplenomegaly
in 3.07% of cases.
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? Nail changes was observed in 69.23% of cases, ridging
(26.15%) being the most common nail change noted.
? Eye involvement was observed in 44.61% of cases.
? Mucosal involvement was observed in 9.23% of cases and
all of them were drug induced erythroderma.
? Eosinophilia and hypoproteinemia was seen in 12.30% of
cases, altered liver function test in 7.69% of cases and raised
level of serum creatinine in 1.53% of cases.
? None of the patients had electrolyte imbalance and metabolic
complications.
? Atypical lymphocytes in peripheral blood smear was seen in
a case of Non Hodgkin’s lymphoma.
? The most common etiological factor was pre existing
dermatosis (61.53%) followed by drug reactions (26.15%),
idiopathic (10.76%) and malignancy (1.53%).
? Among the pre existing dermatosis, psoriasis (30.76%) was
the leading cause followed by eczema (16.92%), ichthyosis
(6.15%), pemphigus foliaceous (3.07%), pityriasis rubra
pilaris (3.07%) and crusted scabies (1.53%).
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? Clinical features were almost identical in nearly all patients.
? Histopathology was rewarding in 43.49% of cases in whom
skin biopsy was performed.
? Drug induced erythroderma had a good prognosis and
erythroderma due to Non Hodgkin’s lymphoma had a worst
prognosis.
Although no etiological diagnosis could be established in a number
of cases it is imperative to follow up and investigate the case periodically
since idiopathic erythroderma may turn to cutaneous lymphoma in the
long run in a percentage of cases.
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PROFORMA
Name Address
Age Occupation
Sex
CHIEF COMPLAINTS:
Itching, burning, shivering
Redness of skin, scaling
Hair lose, nail changes, oral ulcers
HOPI:
Mode of onset (acute or chronic)
Duration of illness
Course of illness
Remissions and exacerbations
Pruritus
Tightness of skin
Photosensitivity
Contact with plants
Joint pain
Fever, malaise, chills
Decreased urine output / leg swelling/ diarrhoea
Breathlessness/ palpitation
Topical applications/ indigenous medicines, drug intake
Seasonal variation, stress, emotional disturbancess
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Focal sepsis , atopy
Suggestive of pre existing skin lesions
 PAST HISTORY
Duration of pre existing skin disease (onset, duration, distribution
and  course of disease.
Similar episodes in the past
Diabetes , hypertension , liver disease , ischemic heart disease.
TREATMENT HISTORY
Drug intake prior to the onset of present illness
Treatment for the present illness elsewhere
Drug taken/withdrawn for preexisting skin disease
PERSONAL HISTORY
Alcohol , smoking
FAMILY HISTORY
Consanguinity in parents
Family members with ichthyosis , immunodeficiency
CLINICAL EXAMINATION
GENERAL EXAMINATION
pallor
Icterus
Clubbing, cyanosis
Pedal edema
Lymphadenopathy (site, size, tenderness, mobility,discrete /matted)
97
VITAL SIGNS
Temperature
Pulse
Blood pressure
Signs of dehydration
SYSTEMIC EXAMINATION
Cardiovascular system
Respiratory system
Abdomen
Central nervous system
Per rectal examination
DERMATOLOGICAL EXAMINATION
Skin erythema
Scaling , types of scaling
Areas of involvement and sparing if any
Skin thickening, lichenification and flaking
Clinical clues of preexisting skin disease.
Scalp- hair loss/ scales
Nail changes
Eye changes
Ectropion of eye lids
Mucosal involvement
CASE
NO AGE SEX ONSET DURATION H/O UD/D R/S I C/R TEMP PE L P/S SCALP NAILS EYES CBC BIOCHEM SKIN/LN/DIF
1 57 M G 3 MON PSORIASIS + + + 39 + - II SC SH,D E AN,EE N CONSISTENT
2 60 M G 6 MON PSORIASIS + + -        N - - N SC,HL SH,PI E AN,EE N CONSISTENT
3 30 M G 1YR IDIOPATHIC + + -        N - + SC,PPK SC PI,RI N N HP DERMATITIS
4 21 M S 10DAYS T. CBZ +  -  + 38.8 +  -  N N N N N N DERMATITIS
5 60 M G 2 MON IDIOPATHIC + + -        N - + N N BL E AN N DERMATITIS
6 58 M S 1WK DRUG +  -  + 38.5 - - PL N N C EO N DERMATITIS
7 2 F G 1YR AD +  + -        N - - N N N N EO N -
8 63 M G 6MON PSORIASIS + + -        N + + II SC PI,OL,BL N EE N DERMATITIS
9 49 F G 10MON PSORIASIS + + -        N - - PPK SC,F D C EE HP CONSISTENT
10 56 M G 3YR IDIOPATHIC + + -        N + - N HL RI N AN,EE HP DERMATITIS
11 31 F S 12DAYS PF + - +        N + - N CR OM,RI C AN,EE N CONSISTENT
12 12 F G 2YR PSORIASIS + + +        N - + FIS,SC N PI,SH N N N CONSISTENT
13 63 M G 20DAYS ABCD +  + + 38 +  + N HL SN N AN,EO N DERMATITIS
14 56 M S 3MON PSORIASIS + + -        N + + II SC SH,D,OL N N N DERMATITIS
15 58 M G 6MON PP +  + + 39 - - N
SC,
HL D, BL E AN ELE DERMATITIS
16 2 FCH  G
SINCE
BIRTH NBIE +  -  -        N - - - N N N N N -
17 50DAYS FCH  G 1MON SD +  -  -        N - - N SC N N N N -
18 71 M G 2MON PPD +  + + 38.5 +  + N HL SN N AN,EO,EE N DERMATITIS
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19 58 M G 3MON IDIOPATHIC + + +        N + + N N SN,D E EE N DERMATITIS
20 55 M S 3WK PPD +  + -        N - - N N SN,D,SH N N HP DERMATITIS
21 60 M S 10DAYS
NATIVE
MED +  + + 39 - - N N N C N N DERMATITIS
22 42 M S 12DAYS T.CBZ +  -  + 38.8 - - PL N N N N N CONSISTENT
23 60 M G 26DAYS PSORIASIS + + +        N + + N SC PI,RI N N N CONSISTENT
24 50 F S 10DAYS T.CBZ + - +        N - + N N BL C N ELE DERMATITIS
25 40 F G 1MON NS +  + +        N + + CR HL SH,D,BL N AN,EE N -
26 29 M S 12DAYS DRUG + - +        N - - N N N N N N DERMATITIS
27 60 M G 6MON PPD +  + -        N + + N HL RI DMF AN N DERMATITIS
28 20 M S 2WK VALPROATE +  -  + 39.4 - - N N N N N ELE CONSISTENT
29 41 M G 6MON PRP +  + -        N - - PPK HL N E N N CONSISTENT
30 25 M S 2WK T.CBZ +  + +        N - - PL N N N N N DERMATITIS
31 61 M G 1YR PSORIASIS + + -        N - - N SC,HL SH,RI E AN HP CONSISTENT
32 17 F S 2WK PP +  -  + 39 - - N SC PI,RI,OM N N N CONSISTENT
33 2mon MCH S 1MON SD +  -  -        N - - N SC N N N N -
34 10 MCH G
SINCE
BIRTH LI +  -  -        N - - SC SC SH E N N -
35 28 F S 1WK ART +  + + 38.6 -  + PL HL BL,RI N AN,EE,EO ELE DERMATITIS
36 18 F G 7MON IDIOPATHIC + + -        N + - PPK HL,SC OL,SH E N N DERMATITIS
37 8 MCH S 1MON PSORIASIS + + -        N - - II SC PI,BL N N N CONSISTENT
38 35 F S 3WK DAPSONE + - + 39 +  + N N N I N ELE DERMATITIS
39 48 M G 1MON PSORIASIS + + -        N + - N SC D,SH N N N CONSISTENT
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40 37 M G 3MON PRP +  + -        N - - PPK N RI N N N CONSISTENT
41 5mon  FCH  G
SINCE
BIRTH LI +  -  -        N - - N N N E N N -
42 53 M G 6MON NHL +  + -        N + + FIS,PPK HL D,SH,OM N
TC74000,LB-
68% N LN BX-NHL
43 23 F S 1WK OFLOX +  + + 39.5 - - PL N N N N N DERMATITIS
44 29 M S 2WK ART +  + +        N - + N N N N AN N -
45 4 FCH  G 3MON AD +  -  -        N - - N N N DMF N N -
46 32 F S 12DAYS PSORIASIS + - +        N - - SC,FIS N N N N N CONSISTENT
47 38 M S 10DAYS CBZ +  -  + 39 -  + PL N N C EO,EE N CONSISTENT
48 43 M G 2MON PSORIASIS + + -        N + - FIS,SC SC SH,OM  N N N CONSISTENT
49 41 M S 5DAYS
NATIVE
MED +  + +        N - - N N N C AN N DERMATITIS
50 52 M G 3MON PSORIASIS + + -        N + - N N RI N AN,EE N CONSISTENT
51 59 M S 2WK PPD +  + +        N + + N N SN,RI C EE N DERMATITIS
52 28 M S 10DAYS
NATIVE
MED +  + + 38.5 + - PL N N N EO,EE N DERMATITIS
53 66 F G 2MON PSORIASIS + + -        N + - N SC SN E EE HP DERMATITIS
54 46 F S 1WK DRUG +  -  + 39 +  + N N N C EE N DERMATITIS
55 60 F G 1MON ABCD +  + -        N - - N HL SN,R N EE N DERMATITIS
56 44 M G 1MON PSORIASIS + - -        N - - FIS SC OL,SH,RI N AN,EE N CONSISTENT
57 1 FCH  G
SINCE
BIRTH LI +  -  -        N - - N SC N E N N -
58 60 M G 4MON IDIOPATHIC + + -        N + + N HL BL,RI E,C EE HP DERMATITIS
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59 55 M S 3MON IDIOPATHIC + + + 39 +  -  N N N N EE N DERMATITIS
60 50 M S 4MON PSORIASIS + - -        N - - FIS,SC SC RI E N N CONSISTENT
61 52 M G 5WK PF + - +        N - - N N RI C AN,EE N CONSISTENT
62 31 F S 2MON ATT +  -  -        N - + SC N N N EO ELE -
63 35 F G 4WK PSORIASIS + + -        N + - N SC PI N N N CONSISTENT
64 2MON  M G 6WK SD +  -  -        N - - N SC N N N N -
65 14 M G 4MON PP +  + + 38.6 + - FIS SC,HL PI,OL E N HP CONSISTENT
KEY TO MASTER CHART
M : Male
F : Female
MCH : Male child
FCH : Female child
+ : Present
_ : Absent
N : Normal
G : Gradual
S : Sudden
H/O UD,D : History of underlying dermatoses, drug intake
AD : Atopic dermatitis
PF : Pemphigus foliaceous
PP : Pustular psoriasis
NBIE : Non bullous ichthyosiform erythroderma
SD : Seborrheic dermatitis
PPD : Phytophotodermatitis
ABCD : Air born contact dermatitis
NS : Norwegian scabies
NHL : Non Hodgkin’s lymphoma
PRP : Pityriasis rubra pilaris
OFLOX : Ofloxacin
CBZ : Carbamazepine
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ART : Antiretroviral therapy
ATT : Antituberculous treatment
R/S : Redness and scaling
I : Itching
C/R : Chills/Rigor
TEMP : Temperature
PE : Pedal edema
L : Lymphadenopathy
P/S : Palms and soles involvement
II : Instep involvement
SC : Scaling
PPK : Palmoplantar keratoderma
PL : Peeling
FIS : Fissuring
CR : Crusting
HL : Hair loss
SH : Subungual hyperkeratosis
D : Onychodystrophy
PI : Pitting
RI : Ridging
OL : Onycholysis
BL : Beau’s line
OM : Onychomadesis
SN : Shiny nails
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C : Congestion
E : Ectropion
I : Icterus
DMF : Denny morgon fold
CBC : Complete blood count
AN : Anemia
EO : Eosinophilia
LB : Lymphoblast
TC : Total count
EE : Elevated erythrocyte sedimentation rate
BIOCHEM : Biochemical investigations
HP : Hypoproteinemia
ELE : Elevated liver enzymes
TZ : Tzank smear
REC : Recurrence
SCR : Scrapping for fungus, acarus
PR : Parthenium
K : Potassium dichromate
LN BX : Lymph node biopsy
DIF : Direct immunofluorecence
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ABBREVIATIONS
CTCL Cutaneous T cell lymphoma
PRP Pityriasis rubra pilaris
HIV Human immunodeficiency virus
PF Pemphigus foliaceous
NS Norwegian scabies
IgE Immunoglobulin E
OPD Out patient department
ART Antiretroviral therapy
ATT Antituberculous treatment
NHL Non Hodgkin's lymphoma
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